Nash

Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March

Retrieved on: 
Tuesday, February 23, 2021
Medical specialties, Clinical medicine, FGF21, Non-alcoholic fatty liver disease, Steatohepatitis, Nash, Hepatitis

Following the live webcasts, archived replays will be available on the Company's website.

Key Points: 
  • Following the live webcasts, archived replays will be available on the Company's website.
  • Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.
  • Akero's lead program, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH.
  • Akero is headquartered in South San Francisco.

Terns to Present at the Cowen 41st Annual Health Care Conference

Retrieved on: 
Tuesday, February 23, 2021
Hepatitis, Tern, Steatohepatitis, Nash, Non-alcoholic fatty liver disease

FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the Cowen 41stAnnual Health Care Conference on Thursday, March 4 at 9:50 a.m.

Key Points: 
  • FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the Cowen 41stAnnual Health Care Conference on Thursday, March 4 at 9:50 a.m.
  • A live audio webcast of the presentation will be available here and on Terns website at http://ir.ternspharma.com/ .
  • A replay of the webcast will be archived on Terns website for 30 days following the presentation.
  • Terns will also participate in a NASH panel at the conference on Tuesday, March 2 from 12:50-1:50 p.m.

Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

Retrieved on: 
Tuesday, February 16, 2021
Medical specialties, Hepatitis, Chemical compounds, Clinical medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Nash, Tropifexor, Obeticholic acid

Metacrine has developed a proprietary FXR platform utilizing a unique chemical scaffold, which has demonstrated a differentiated and improved therapeutic profile in the clinic.

Key Points: 
  • Metacrine has developed a proprietary FXR platform utilizing a unique chemical scaffold, which has demonstrated a differentiated and improved therapeutic profile in the clinic.
  • MET409 is a once-daily, orally administered FXR agonist that is being evaluated as both a monotherapy and a combination therapy for the treatment of NASH.
  • The Journal of Hepatology article, entitled A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis , was published online on February 11, 2021.
  • The companys two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).

Global Liver Institute Releases Comprehensive U.S. NASH Action Plan

Retrieved on: 
Tuesday, February 9, 2021
Medical specialties, Hepatitis, Clinical medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Liver, Nash, Tropifexor

Washington, DC, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) and the GLI NASH Council have released the U.S. NASH Action Plan to comprehensively address nonalcoholic steatohepatitis (NASH), the advanced form of nonalcoholic fatty liver disease (NAFLD), and its impact on patients and families, public health, and the economy.

Key Points: 
  • Washington, DC, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) and the GLI NASH Council have released the U.S. NASH Action Plan to comprehensively address nonalcoholic steatohepatitis (NASH), the advanced form of nonalcoholic fatty liver disease (NAFLD), and its impact on patients and families, public health, and the economy.
  • Recommendations from the U.S. NASH Action Plan for GLI NASH Council members and the larger health community include:
    Education increasingly tailored for at-risk patient populations, in-language and in-culture.
  • Global Liver Institute (GLI) is a 501(c)(3) tax-exempt not-for-profit organization, headquartered in Washington, D.C., United States, with offices in the U.S. and Europe.
  • GLI's vision is for liver health to take its place on the global public health agenda commensurate with its prevalence and impact.

Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”

Retrieved on: 
Thursday, January 28, 2021
FDA, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Liver, Hepatitis, Non-alcoholic fatty liver disease, Anatomy, Fatty liver disease, Liver disease, Nash, Bile acids, Melissa Palmer, Steatohepatitis

Can-Fites drug candidate Namodenoson completed a successful Phase II study in the treatment of non-alcoholic fatty liver disease (NAFLD)/NASH which met its endpoints.

Key Points: 
  • Can-Fites drug candidate Namodenoson completed a successful Phase II study in the treatment of non-alcoholic fatty liver disease (NAFLD)/NASH which met its endpoints.
  • The Company is currently preparing a Phase IIb study for Namodenoson in the treatment of NASH, the protocol for which has been designed by Dr. Harrison and other KOLs.
  • Dr. Harrison went on to indicate that future trials of Namodenoson in the treatment of NASH would target the population at greatest risk, those with some degree of fibrosis.
  • Dr. Harrison is Medical Director of Pinnacle Clinical Research, a gastroenterologist, and hepatologist specializing in metabolic liver disease.

Akero Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 4, 2021
Biotechnology, General Health, Health, Clinical trials, Medical specialties, Clinical medicine, Branches of biology, Steatohepatitis, Non-alcoholic fatty liver disease, Nash, Hepatitis, Metabolic disorder

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 10:50 a.m. EST on Tuesday, January 12, 2021.

Key Points: 
  • Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 10:50 a.m. EST on Tuesday, January 12, 2021.
  • A live webcast of the presentation will be available through the investor relations section of the Company's website at www.akerotx.com .
  • Following the live webcast, an archived replay will be available on the Company's website for 30 days.
  • Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health.

$27.2 Billion Non-Alcoholic Steatohepatitis (NASH) Opportunity Analysis and Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 9, 2020
Health, Pharmaceutical, Medical specialties, Anatomy, Clinical medicine, Histopathology, Steatohepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Hepatitis, Liver disease, Steatosis, Alcoholic liver disease, Nash

The "Non-Alcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Alcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage.
  • Both NASH and non-alcoholic fatty liver (NAFL) are histologically categorized under the umbrella of non-alcoholic fatty liver disease (NAFLD).
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of pipeline products.

Akero Therapeutics to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference

Retrieved on: 
Tuesday, November 24, 2020
Professional services, Health, Finance, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Medical specialties, Clinical medicine, Medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Nash, Hepatitis

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercores 3rd Annual HealthCONx virtual conference at 11:20 a.m.

Key Points: 
  • Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercores 3rd Annual HealthCONx virtual conference at 11:20 a.m.
  • A live webcast of the fireside chat and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com .
  • Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health.
  • Akero Therapeutics is headquartered in South San Francisco, CA.

Helping NASH Study Sites to Succeed: Insights into Operational Best Practices, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 23, 2020
Nash, Cars, Vehicles, Automotive industry

In this challenging landscape, how can pharma and biotech companies ensure that their NASH trial sites are set up for success and best supported to drive the development of new therapies?

Key Points: 
  • In this challenging landscape, how can pharma and biotech companies ensure that their NASH trial sites are set up for success and best supported to drive the development of new therapies?
  • Get insights and feedback from our extensive NASH study experience, and the findings from ICON's recent survey of more than 2,000 sites across 30 countries.
  • We will discuss the operational data compiled and shared through questionnaire responses on best practices for NASH study sites.
  • For more information, or to register for this event, visit Helping NASH Study Sites to Succeed: Insights into Operational Best Practices.

Terns Pharmaceuticals Appoints Industry Veteran Bryan Yoon as Chief Operating Officer and General Counsel

Retrieved on: 
Monday, November 16, 2020
Biotechnology, Pharmaceutical, Health, Life sciences, Hepatitis, Biotechnology, Health sciences, Specialty drugs, Steatohepatitis, Non-alcoholic fatty liver disease, Biopharmaceutical, Nash

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced today the appointment of Bryan Yoon as Chief Operating Officer and General Counsel.

Key Points: 
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced today the appointment of Bryan Yoon as Chief Operating Officer and General Counsel.
  • Bryan brings significant operational, strategic, and legal expertise as well as life sciences experience to Terns, adding further strength to our executive team, said Senthil Sundaram, Chief Executive Officer of Terns.
  • Mr. Yoon commented, NASH is an area of high unmet need with no approved therapies.
  • Prior to becoming Chief Operating Officer and General Counsel at Terns, Mr. Yoon served as the Chief Administrative Officer, General Counsel, and Secretary of LogicBio Therapeutics.